Soleno Therapeutics, Inc.
(NASDAQ : SLNO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
DXCMDexCom, Inc. 4.56%378.318.2%$1034.33m
ABTAbbott Laboratories 3.17%95.020.8%$681.99m
BDXBecton, Dickinson & Co. 2.27%246.971.0%$635.38m
DHRDanaher Corp. 1.51%166.440.7%$595.38m
MDTMedtronic Plc 0.61%98.740.6%$552.61m
TMOThermo Fisher Scientific, Inc. 1.81%348.941.0%$507.16m
INOInovio Pharmaceuticals, Inc. 10.49%14.756.3%$439.97m
BSXBoston Scientific Corp. 1.36%37.981.1%$409.30m
ISRGIntuitive Surgical, Inc. 1.34%580.032.4%$370.20m
SYKStryker Corp. 0.23%195.791.3%$362.87m
WSTWest Pharmaceutical Services, Inc. 5.30%216.941.6%$307.41m
ALGNAlign Technology, Inc. -1.43%245.626.4%$296.78m
BAXBaxter International, Inc. 2.00%89.961.8%$262.76m
EWEdwards Lifesciences Corp. 1.09%224.561.2%$220.18m
QDELQuidel Corp. 4.65%175.007.7%$217.06m

Company Profile

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.